MedTrace Logo

Capecitabine in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00006023 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2019-06-26

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.

Conditions

Interventions

DRUG

capecitabine

Sponsors & Collaborators

  • Swiss Cancer Institute

    lead OTHER

Principal Investigators

  • Rudolf Morant, MD · Cantonal Hospital of St. Gallen

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-03-31
Primary Completion
2001-06-30
Completion
2001-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006023 on ClinicalTrials.gov